Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I do, I truly do.
Denner's not happy nor satisfied and he can change things. You should really go away because you no invested here, right? No shares, no voice. Beat it Pharmacydude.
BOD owes a 'Letter to Shareholders' led by Berg writing it.
Hey it's my money so I'll say it.... Holt looked 50 lbs overweight at recent conference... He certainly didn't look anything close to website... he's a FAT CAT. Now he's gone! I think he numbers among the top CEO BS' errrrrrr
Is CVS country wide or is this an individual state?
would it make sense Denner's BOD appointed Berg BECAUSE they were unhappy with his performance in the USA? I find that very doubtful.
Maybe Berg OUTSHINED Holt in the eyes of the BOD?
Holt was an opportunist who has gotten a better opportunity from his standpoint. There's nothing to 'read' into this. Berg was the natural choice as he knows the company inside and out. Denner's BOD handled the transition in a quick, tidy manner and I highly doubt the Denner game plan has changed: Continue to prepare the firm for sale. I perceive the Denner BOD is driving the firm and the CEO (now Berg) will execute per BOD directives.
Not everyone is a statin user, or tolerant to statins.
IMO I'd love to see a study without statins, but not paid for by Amarin but by its acquirer. That would LAUNCH Vascepa/Vazkepa to the stars!!! Seriously.... (BTW, statins limiting cholesterol may have a brain affect called Alzheimer's -- not a joke).
The fact Amarin plans to spend up to $50M on the BB tells you they plan to sell the company. They're not spending it on advertising, building out another sales staff, not a new product, research, nope, nope, nope. Spending $50M on BB because they can as they move into the 6-12 mth window as the year goes on to sell the company. It is smart because it not only tightens the float, squeezes shorts, raises current shareholder holdings, it's obvious Amarin is saying it has enough cash on hand to get to the finish line--selling the company. So what's the time-frame for the BO? First-half next year when France and Italy are both known (good or bad). HFs will want in on the ride so there's going to be a lot of smart investors showing up.
Any BP with a CVD portfolio can add Vascepa/Vazkepa in a heartbeat to drive sales. The USA is still worth billions as is the ROW and EU. This isn't about naively trusting Denner, Holt, or the BOD, this is about everyone on board wants to make a ton of money. You buy Amarin shares because you think you can make a ton a money. Plain, simple, fact. All risk assumed. A savvy investor only needs to score once in biotech land to walk away with millions. My money remains on the Vascepa/Vazkepa enterprise. And I accept all risk.
I have to laugh at this post because it implies something I do not. Denner, Holt, et al at Amarin all want what I want. To make as much money as possible. Myself, I don't think Denner is awake at night thinking about investors, but I do think he wants as much as he can get. Here's my point: I'm happy to ride his coattail because I doubt I'll be disappointed in the end, and I know all about risk. Thanks!
Are we forgetting a BP w sales infrastructure in USA could immediately piggyback Vascepa with its CVD portfolio and go after millions to billions via brand n generic? What BO BP will do is what Amarin shouldn’t as Holt prepares for a 2025 sell IMO
IMO share bb expense will be recovered in driving a much higher pps, as the float will shrink and leaked info among HFs the BO is near will drive the pps up. For a premium pps we must get Italy and France. Plus some BP must be influencing Holt on partnerships like Middle East etc. Holt’s entire job is to ready the sale which as an investor himself he n his friends all want like us the big payout. I still think $15 and above is his contracted payout premium for Holt
IMO gaining France and Italy (Germany can be left to acquiring firm) are in fact the last two goals to drive the highest value to sell Amarin. The outcome will determine the sale price. i don’t see any other major goal since BP will drive its own sales strategy. Gaining CVD approval in China may be another goal but probably just needs to appear favorable. The share bb tightens up the float. IMO if Amarin announced a second generation Vascepa patent protectable in the USA via Mochida, it’s possible as they are spending $5M Q in R&D on something. i remain optimistic the BO will be north of $15/pps. Italy and France (2025) lead me to think the BO will be 2025 to a EU strong BP
IMO share buy back will be spread over 2024, $5M here, there, but also tied to how revenues hold up. $10M maybe to start IMO
I'm 3 months into grieving. I recently bought on the science another 10,000 shares.
But I know pain. I know a lot. 40 yrs later my best friend is gone. Thanks for encouraging me.
xx yrs later (2024) I lost my soulmate to cancer. We were married decades.
I'm currently investing hundreds of millions for our children and grandchildren in Amarin. Why? The science and Denner/Holt took over. One day WS will re-awake that Vascepa is prolonging life in a big way. IMO everything Holt is up to is to sell the firm at a premium; no criticism from ...5... 10... 20 I profit.
At anything $10/share I'm a very wealthy man. $5 I'm moderately wealthy. I can't lose.
I think a lot of people here have their own story.
Thanks everyone for schooling me on E-EPA! It was an amazing ride! I got a lot of laughs!
From now on Vascepa will be Elektra-EPA for me! I nominate Jennifer Garner to advertise once she's available.
Our discussion is over because you either work for Amarin and are embarrassed, or you don't understand as a lesser mind how even one element from the periodic table may make the end-product novel. Vascepa is E-EPA, not EPA. Or maybe you work for Hikma? It's always possible.
IF you do not grasp the implication of periodic chart, I'm sad for you (and hopefully I am wrong). Vascepa is not EPA. It is E-EPA. Any astute lawyer would exploit this.
Mori et al NEVER STUDIED E-EPA. Never! Amarin patented E-EPA. In court, Amarin should defended what it patented, and THERE IS NO PRIOR ART of E-EPA. 'Judge Du we are in court to defend E-EPA and Hikma doesn't seem to be aware of Vascepa's chemistry. Dismiss the case!'
If you can't grasp this, our discussion ends, but I could line up thousands of chemists who would testify E-EPA is not EPA because the molecule is different explained by processes undertaken in the lab.
Fact: It doesn't matter if one carbon, one hydrogen, one oxygen, one whatever is added, it is unique. VASCEPA IS NOT EPA!!! If you have an ounce of intelligence, let that sink in!!!! Amarin is defending E-EPA!!!!!
Amarin should create an E-EPA patent distinguished from EPA. In a real sense, they already have, but Amarin's lawyers don't seem to grasp what they are defending (E-EPA). In lawyer land this is not a mote point. In court, Amarin should have told Judge Du 'we are defending E-EPA, not EPA' and I appeal to Marjac who had mud thrown in his face. Vascepa is E-EPA, not EPA and now our chemist friends are coming out to explain why. I am convinced Holt and his team are yet to grasp this.
Any schooled, educated, astute lawyer would grasp EPA is not E-EPA.
A molecule can go from good to bad on one change. Amarin's fiduciary responsibility is to defend E-EPA, not EPA. Hikma built its entire case around EPA and how it was not novel. I wish a lawyer on this IHUB board would grasp what this means. Hikma defended EPA research, and Amarin's lawyers fell prey.
Amarin is selling E-EPA and even Captain and many others need to grasp this. Thank you on the weekend.
Amarin needs to start defending E-EPA, and the way back to Judge Du.
You expecting me to cry?
dear friend, we are all on the same page...
You have just given a patent reason why Amarin patented E-EPA if I repeat your post "it is the way they can concentrate enough EPA to get 1,000mg into a swallowable pill." If I agree/submit without agreeing to your assertion why Vascepa is E-EPA and not EPA, you actually proved why Amarin lawyers should be defending E-EPA in the court of law.
All the best.
Aha! You actually prove my argument if you are correct and I won't debate that now.
Amarin "discovered" E-EPA was necessary, and no prior art addressed this. NONE.
Amarin discovered E-EPA was a necessary step to induce EPA into the body (your insight). Amarin clearly understood pre- and phase 1 studies EPA alone could not be put into a capsule in comparison to E-EPA which via efficacy and safety achieved the desired outcome.
E-EPA is not EPA. Fact. You are better educated than me, but E-EPA and EPA are not the same. Tell everyone on IHUB they are the same... you won't, you know the truth. Let's work together my friend.
I think this discussion is necessary, but I disagree with the suggestion "EPA is the active moiety" and could not be affected negatively or positively by turning it into an ethyl ester. Amarin had clear reasons for turning it into an ethyl ester and every patent going back to the beginning, states E-EPA.
IHUB friends: Any change in the chemical chain is the basis for the patent Amarin claimed. Amarin claimed E-EPA, not EPA. For some patented reason, Amarin determined adding the Ester Ethyl was necessary, and every since has cited it in every claim section of patents. The fact is turning EPA into E-EPA is not a mote "moiety" point. There are efficacy issues, safety issues, a lot of issues!!!!
In court, Amarin is there to defend E-EPA.
I entirely disagree (respectfully).
Amarin altered in the lab EPA into E-EPA for a valid, patented reason. They in the patents even cite other possible indications. Keep in mind number sleven, E-EPA, a chemical composition could have negatively or positively affected the EPA moiety. Amarin clearly did early studies which led them to the Ethyl Ester version, and for a REAL reason.
In a court of law, a lawyer, an astute lawyer would have argued EPA is not E-EPA, as the chemistry is not the same, and it's not the same. If you cannot see how a lawyer cannot argue EPA is not E-EPA, then I wonder in due respect. A Lincoln is not a Mercury though made by the same firm.
Hikma lawyers focused on the prior art of EPA, not E-EPA. I think Marjac would side with me, as would other lawyers. But let's keep the discussion going. All the best!
It's embarrassing (and costing all of us billions) but Amarin, its opponents (maybe knowingly), and naive non-chemist judges... WELL GANG, they've all been arguing over the wrong chemistry. FACT: Vascepa is not EPA. Vascepa is E-EPA. Eh Marjac? Eh Amarin? Eh Holt?
I know enough that ethyl ester was added for a patent-safety-efficacy reason. Bank on it. And here's the fact Jack: there is no prior art like Mori focused on E-EPA, otherwise prove me wrong.
Amarin Needs to Defend the Right Molecule in Court: E-EPA (C22H34O2).
All of Amarin's patents claim E-EPA.
In Nevada, Amarin argued with Hikma over EPA (prior art). Big glaring mistake!
E-EPA is a novel, lab created, molecule, not found in fish oil.
Hopefully, there is time and opportunity for Amarin to return to court and defend E-EPA, not EPA.
Catch this every claim section of Vascepa patents are E-EPA, not EPA. EVERY PATENT, EVERY! E-EPA
8557280 ***WITHDRAWN PATENT AS PER THE LATEST USPTO WITHDRAWN LIST***
8557799 ***WITHDRAWN PATENT AS PER THE LATEST USPTO WITHDRAWN LIST***
8518929 Methods of treating hypertriglyceridemia
8524698 Methods of treating hypertriglyceridemia
8546372 Methods of treating hypertriglyceridemia
8551521 Stable pharmaceutical composition and methods of using same
...ALL THE WAY INTO THE PRESENT. E-EPA.
Amarin is in court to defend E-EPA, not EPA. Again, Amarin had patent reasons for adding ethyl ester. There is no prior art focused on E-EPA. I sure hope someone is listening at Amarin.
Patent 11690820 "4. The composition of any one of claim 1, 2, or 3 wherein the ethyl-eicosapentaenoic acid is present in the composition in an amount of 250 mg to 1000 mg. 5. A pharmaceutical composition comprising 250 mg to 1000 mg of fatty acids at least 95% of which are in the form of ethyl eicosapentaenoic acid, wherein the composition contains no docosahexaenoic acid, and the composition is present in a capsule. 6. A pharmaceutical composition comprising 250 mg to 1000 mg of fatty acids at least 95% of which are in the form of ethyl-eicosapentaenoic acid, wherein the composition contains (a) less than 5% in aggregate of arachidonic acid and n-3 docosapentaenoic acid, and (b) no docosahexaenoic acid; and wherein the composition is present in a capsule."
Patent 8557280 "1. A method of reducing triglycerides in a subject in need thereof who is on statin therapy comprising, administering to the subject 2500 mg to 5000 mg per day of ethyl eicosapentaenoate for a period effective to reduce triglycerides in the subject. 2. The method of claim 1 wherein the ethyl eicosapentaenoate is administered to the subject in dosage units each comprising about 500 mg to about 1.5 g of ethyl eicosapentaenoate 4. The method of claim 1 wherein the ethyl eicosapentaenoate is administered to the subject in dosage units each comprising about 900 mg to about 1 g of ethyl eicosapentaenoate. 6. The method of claim 1 wherein the ethyl eicosapentaenoate is administered to the subject in dosage units each comprising about 1 g of ethyl eicosapentaenoate. . The method of claim 1 wherein the ethyl eicosapentaenoate is present in a pharmaceutical composition comprising other fatty acids or esters thereof and said ethyl eicosapentaenoate comprises at least about 90%, by weight, of the fatty acids present in the composition."
Patent 8557799 "3. The method of claim 2 wherein upon administering the composition to the subject daily for said period, the subject exhibits a reduction in fasting VLDL-C compared to a fasting VLDL-C level in a subject maintained on stable statin therapy without concomitant ethyl-EPA for said period. 4. The method of claim 3, wherein upon administering the composition to the subject daily for said period, the subject exhibits at least a 15% reduction in fasting triglycerides compared to a fasting triglyceride level in a subject maintained on stable statin therapy without concomitant ethyl-EPA for said period. 5. The method of claim 4, wherein upon administering the composition to the subject daily for said period, the subject exhibits a reduction in fasting LDL-C compared to a fasting LDL-C level in a subject maintained on stable statin therapy without concomitant ethyl-EPA for said period. . A method of lowering triglycerides in a subject on stable statin therapy having fasting triglycerides of about 200 mg/dl to less than 500 mg/dl and a fasting LDL-C level of about 40 mg/dl to about 100 mg/dl comprising, orally administering to the subject daily for a period of at least about 4 weeks a pharmaceutical composition comprising about 4 g of ethyl-EPA and not more than about 4% DHA or its esters, by weight of all fatty acids present. 10. The method of claim 9 wherein upon administering the composition to the subject for said period, the subject exhibits a reduction in fasting non-LDL compared to a fasting non-LDL level in a subject maintained on stable statin therapy without concomitant ethyl-EPA for said period. 11. The method of claim 9 wherein upon administering the composition to the subject daily for said period, the subject exhibits a reduction in fasting VLDL-C compared to a fasting VLDL-C level in a subject maintained on stable statin therapy without concomitant ethyl-EPA for said period. 12. The method of claim 9 wherein upon administering the composition to the subject daily for said period, the subject exhibits a reduction in fasting non-HDL-C compared to a fasting non-HDL-C level in a subject maintained on stable statin therapy without concomitant ethyl-EPA for said period. 13. The method of claim 9 wherein upon administering the composition to the subject daily for said period, the subject exhibits a reduction in fasting total cholesterol compared to a fasting total cholesterol level in a subject maintained on stable statin therapy without concomitant ethyl-EPA for said period. 14. A method of lowering triglycerides in a subject on stable statin therapy having fasting triglycerides of about 200 mg/dl to less than 500 mg/dl comprising, administering orally to the subject on statin therapy a pharmaceutical composition comprising about 4 g per day of ethyl-EPA and not more than about 4% DHA or its esters, by weight of all fatty acids present, for a period of at least about 4 weeks thereby to lower fasting triglycerides in the subject by at least 15% compared to a fasting triglyceride level in a subject maintained on stable statin therapy without concomitant ethyl-EPA for said period, and wherein administration of the composition results in a statistically significant reduction in fasting LDL-C compared to a fasting LDL-C level in a subject maintained on stable statin therapy without concomitant ethyl-EPA for said period. "
It's E-EPA, Amarin has a clear path to reinstate the patents.
List the 6 patents and I will research with quotations from each patent particularly the claim section.
According to my read, Amarin lost to Hikma because Judge Du and the lawyers argued over the prior art issue of EPA (Mori, etc). Yet E-EPA is not in prior art and is a novel creation in the lab. In this case, this is clear fault of Amarin's lawyers not to point out the obvious: Hikma argued there was EPA prior art (debatable), but what would have ended the whole case is if Amarin's lawyers pointed out they were there to defend E-EPA of which there is no prior art. I also wish Captain and others on this board would grasp: "IT'S THE E-EPA STUPID!" on his many wonderful charts. 😃
For those still wrestling to grasp why E-EPA is important, is because Amarin's inventors would tell you the reason (safety, absorption without harm, many reasons, etc.) why they added the ethyl ester to the EPA chemical chain). I can already guarantee all of you there were clear reasons why Amarin's inventor added the Ethyl Esther. I hope this helps advance knowledge.
IMO the buy-back will cut into share supply and set the stage for a faster-rising share demand as if I remember Amarin has hefty percentage of long-investors (private and institutional). Furthermore, Amarin is selling E-EPA (C22H34O2), not EPA (C20H30O2), thanks for ORBAPU for clarification, just dig into patent 11690820 "Claim 5. The pharmaceutical composition of claim 1, wherein the eicosapentaenoic acid is ethyl eicosapentaenoate"... E-EPA is a novel creation in the lab; EPA is found in fish. I regret not one legal-beagle to date has yet to grasp what Amarin's lawyers were supposed to be defending in court: E-EPA, not EPA. There was definitely no prior "art" regarding E-EPA which meant the opposition's citing of prior art was EPA, not E-EPA created in the lab, not found in fish. Just look at the chemical chain; they are not the same. "Your honor Judge Du, we are here to defend E-EPA, not EPA, as there is no prior art for E-EPA. Our opponents Judge are talking about the wrong molecule. We rest our case."
Myself not being a chemist but once working for a chemist the following HIT ME LIKE A TON OF BRICKS.
Quote from ORBAPU: "Icosapent ethyl or ethyl eicosapentaenoic acid is a synthetic derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA)"... in another post he/she wrote "IPE does not occur in nature"... earlier he/she posted on the chemistry.
I AM EMBARRASSED AT MY OWN IGNORANCE!
I am equally embarrassed no one schooled Amarin's lawyers (in the past before Judge Du), the case before her was NOT OVER EPA, BUT IPE!!!! Do any of you lawyers see what I'm saying? IPE, not EPA, was the invention protected by the patents!!! I am so blown away right now, by this revelation.
The opposition before Du focused on an EPA argument, and Amarin's uninformed non-chemist lawyers fell right into the trap. "JUDGE DU!" Amarin's lawyer should have shouted, "This case IS NOT ABOUT EPA, it's about Amarin's IPE invention! Judge Du, the opposition presents articles all focused on EPA, not IPE! Fish are not swimming about with IPE in them!"
Now there are a lot smarter people than me on IHUB, so what do you think? If I were hence promoting Vascepa/Vazkepa my slogan would read: "It's NOT old smelly fish oil EPA, it's IPE, a synthetic invention of Amarin not found in nature."
Feedback?
Were I a lawyer and I am not, Mr. Stockboy muses.
1. I'd first establish in facts, there is clear evidence generic firms are benefiting from taking 43% from at best 10% skinny law intention. I'd offer a simple pie chart easy to understand.
2. I'd second establish in facts, the actual percentages of that 43% particularly highlighting Hikma's lion's share of that 43% and how Hikma clearly premeditated its path in the majority of abuse of the skinny law.
3. Now three, I'd connect Hikma as guilty as accused by the premeditated facts. I'd then drive home Hikma's documented intention to exploit to their benefit the non-skinny indication. Spell it out in simple terms how 'How Hikma knew in advance how they could get away with going around the skinny label law.'
4. I'd even quote Judge Du who acknowledged her decision would hurt Amarin's revenues, making it clear the skinny label law is being abused, Amarin has suffered incredible losses, and millions of potential patients are not even benefiting from this life saving drug because Amarin's loss has crippled the firm to such a degree a 600 sales force was terminated and today thousands of physicians still don't know about Vascepa. Meanwhile, Hikma flaunts the intent of the skinny label law and in turn millions of CVD patients don't even know about Vascepa.
5. Taken all the evidence against Hikma, it was clear they promoted and planned, premeditated, and even have led the way making them culpable for its actions and are liable for breaking the intent for the skinny label law.
6. Finally, present the nail in the coffin. A head to head analysis of the Vascepa capsule vs the Hikma so-called generic. Create doubt, lots doubt, and NEVER APPROVED BY THE FDA FOR CVD and any jury despite Hikma's skinny label approval, their generic is in fact an inferior generic which they are selling to the public by an illegal end-around breaking of the skinny label law.
Keep it factual. Keep it simple. lET THE TRUTH PREVAIL. Smear the EPA all over Hikma's face.
I'm no expert but it sure seems like Amarin is in the process of 'dislodging' Hikma to a tune of millions of dollars. Judge Moore is an example of a righteous judge. I am thankful Amarin's new leadership has done a much much better job choosing lawyers.
USA market. Since I haven't posted much, maybe I'll feel better if I express something going back recent years post-Du, I still don't "get"... Why the assumption the USA market is lost? Yes, generic competition did account for a hefty loss, but to control about 60% of the market spells OPPORTUNITY. Furthermore, expanded effort means making the creative effort to make that market grow, yes generics will benefit, but so can/will Amarin. IMO, what seems to have failed was the old-style strategy to market Vascepa, and I thought Holt would bring a new strategy; to a degree he has, but it's still not tapping the thousands of potential patients who could be buying and benefiting from using Vascepa. For example, Amarin appears to be clueless about the potential of social media. I know doctors use to get free samples (Is that illegal today? I don't know, but if not, why not give a month's trial size to a thousand physicians across the USA? The other night on Shark Tank a kid was given a deal selling his bow-ties... another guy socks... there's lots of competition, but competition doesn't mean you can't be a success if you know how to market your product. For example, Amarin ignores its Vascepa capsule is the best capsule (or isn't it?). Amarin ignores publicly addressing quality issues and capsule longevity or how generic versions smell (I tested Hikma and Teva and it was true, they stunk). It seems like Amarin doesn't know how to tell its Vascepa story and continues to falter in this important area. Meanwhile, we never hear about sales goals for the USA, but it's more like 'we're just polishing up the company and need to secure at 2 or 3 (Germany, France, Italy)' to secure a BO; well, maybe that's true, but I still don't understand why there's this attitude 'the USA was lost post-Du'. No, that was never true. Yes, it would mean a potentially big hit to revenues, but even right now it appears Amarin has Hikma on the ropes in court. Do I feel better now? I don't know. Whatever!